GlassScriptPhysician profile
Samuel Baharestani
NPI 1730355116
$134,545.82
in general payments reported to CMS, 2019-2025
25 companies · $39K in 2025
The $39K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,045 · 2020: $2,572 · 2021: $1,933 · 2022: $413 · 2023: $45K · 2024: $45K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70K · Honoraria: $39K · Food and Beverage: $7,594 · Travel and Lodging: $6,542 · Consulting Fee: $5,100 · Education: $10.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $69,912.50 |
| Honoraria | $39,423.75 |
| Food and Beverage | $7,594.48 |
| Travel and Lodging | $6,542.07 |
| Consulting Fee | $5,100.00 |
| Education | $10.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $82,555.39 | 2024-2025 | Tepezza, Uplizna |
| Horizon Therapeutics Plc | $48,153.18 | 2019-2023 | Tepezza |
| Merz North America, INC. | $2,139.69 | 2019-2023 | Xeomin |
| Ani Pharmaceuticals, INC. | $293.00 | 2024-2025 | Purified Cortrophin Gel |
| Tarsus Pharmaceuticals, INC. | $214.38 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $178.49 | 2024-2025 | Simbrinza |
| Oyster Point Pharma, INC. | $139.40 | 2022-2025 | Tyrvaya |
| Vericel Corporation | $132.96 | 2025 | Nexobrid |
| Rxsight INC | $130.96 | 2023 | Rxsight Injector Handpiece, Rxsight Light Adjustable Lens (Rxlal), Rxsight Light Delivery Device (Ldd) |
| Revance Therapeutics, INC. | $95.13 | 2024 | Daxxify |
| Harrow Eye, LLC | $83.33 | 2024 | |
| Bausch & Lomb Americas INC. | $66.22 | 2023-2025 | Doctors Allergy Formula |
| Galderma Laboratories, L.P. | $51.36 | 2019-2022 | |
| Shire North American Group INC | $42.51 | 2019 | |
| Eyevance Pharmaceuticals LLC | $41.76 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $40.77 | 2020 | |
| Sun Pharmaceutical Industries INC. | $40.44 | 2019-2025 | |
| Biotissue Holdings INC. | $32.05 | 2023 | |
| Sight Sciences, INC. | $23.41 | 2022 | |
| Dompe US, INC. | $18.27 | 2020 | |
| Tearlab Corp | $17.79 | 2024 | Scoutpro Osmolarity System |
| Abbvie INC. | $16.88 | 2023 | Botox |
| Allergan, INC. | $13.50 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.59 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Baharestani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.